Organization
Perlmutter Cancer Center, New York University Langone Health
18 abstracts
2 posters
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731.Org: Adaptive Biotechnologies, Baylor College of Medicine, Servier Pharmaceuticals, Perlmutter Cancer Center, New York University Langone Health, University of Washington School of Medicine,
Abstract
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.Org: University of Pittsburgh Medical Center Hillman Cancer Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan College of Medicine,
Abstract
Predicting completion of endocrine therapy for older patients with early-stage breast cancer.Org: NYU Langone Medical Center, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Health,
Abstract
Association of food insecurity with reduced cancer screening rates.Org: NYU Long Island School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Oncology-Hematology, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Hospital,
Abstract
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).Org: Columbia University Irving Medical Center, New York, NY, USA, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Montefiore Einstein Comprehensive Cancer Center, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Health,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx).Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, NYU Perlmutter Cancer Center, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.Org: Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.Org: City of Hope- Long Beach Elm, Perlmutter Cancer Center, New York University Langone Health, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UT Southwestern Medical Center, Hôpital Pitié-Salpêtrière, NYU Department of Urology, Perlmutter Cancer Center, New York University Langone Health,
Abstract
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.Org: Blueprint Medicines, Sarah Cannon Research Institute/Tennessee Oncology, Perlmutter Cancer Center, New York University Langone Health, Gustave Roussy, Department of Medical Oncology, Thoracic Group,
Abstract
Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, SWOG, Hospital Clinic of Barcelona, Perlmutter Cancer Center, New York University Langone Health,